Table 1 Laboratory features to evaluate the disease activity and therapeutics used in SLE patients at the time of sampling

Disease activity

SLEDAI

20 (8–24)

General laboratory features

Total leukocyte count (× 10⁹ × L)

5.087 (4–10.1)

Total neutrophil count (× 10⁶ × L)

5087 (3266–7979)

Total lymphocyte count (× 10⁶ × L)

1390 (846–1847)

Neutrophil/lymphocyte index

8 (1–19)

Hemoglobin (g/dL)

10.5 (6.6–13.7)

Creatinine (mg/dL)

1.8 (0.6–5.19)

C3 (mg/dL)

57 (32–110)

C4 (mg/dL)

8 (8–28)

Proteinuria (mg/24 h)

7555.3 (1866–19,564)

Proteinuria-Creatinuria Index (CPI) g/g

5.78 (1.5–14.5)

Immunological tests

Anti-DNAdc IgG (ELISA-FARR) (IU/mL)

141.1 (2.1–658)

Anti-Nucleosomes (U/mL)

209 (11.4–659.7)

IgM anti-cardiolipin (UMPL)

10.9 (7.3–33.8)

Anti-cardiolipin IgG (UGPL)

8.95 (4.7–65.3)

Anti-β2glycoprotein I IgM (U/mL)

4.3 (3–14.2)

Anti-β2glycoprotein I IgG (U/mL)

4.05 (2.8–72.5)

Positive lupus anticoagulant

20%

Immunosuppressive therapy

Prednisone dose (mg/day)

51.8 (10–70)

Azathioprine dose (mg/day)

1.25 (1.25–1.25)

Mycophenolic acid dose (gr/day)

3 (2.5–3)

Cyclophosphamide dose (gr/month)

1 (0.8–1.4)

Dose of hydroxychloroquine (mg/day)

200 (150–400)